Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) -- Ignore unavailable to you. Want to Upgrade?

To: RRICH4 who wrote (1432)	2/16/1999 12:02:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 1722

Lilly Launches New Insulin Pens Tuesday February 16 11:04 AM ET WASHINGTON (Reuters) - Eli Lilly and Co. (NYSE:LLY - news) said Tuesday it has launched a series of new easy-to-use insulin pens for diabetics after receiving Food and Drug Administration (FDA) approval. The pre-filled pens are meant to make it easy for patients to give themselves doses of insulin anywhere and at any time. The FDA approved the three new devices in August but the company waited to make an announcement until the product was on the shelves, a company spokeswoman said. Pens containing Humulin 70/30 and Humulin N are available over the counter, while pens filled with a quick-acting insulin called Humalog are only available by prescription, a spokeswoman said. Lilly said the pens allow users to choose the correct dose. ''The patient simply turns a dose knob, which can be dialed forward or backward in single unit increments,'' it said in a statement. More than 16 million Americans have diabetes, most of them the type-II diabetes that only sometimes requires insulin injections. For the million or so Americans with type-I diabetes, insulin is a daily requirement. Lilly and several other companies are working on forms of insulin that can be inhaled, which would do away with the need for injections. Humulin is a genetically engineered version of human insulin meant to be identical to natural insulin, while Humalog, also genetically engineered human insulin, is designed to mimic the body's rapid production of insulin after a meal.